Delayed
Japan Exchange
12:53:48 2024-06-05 am EDT
|
5-day change
|
1st Jan Change
|
2,481
JPY
|
-1.33%
|
|
+0.18%
|
-6.81%
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
156,406
|
129,800
|
211,857
|
165,227
|
151,722
|
142,871
|
-
|
-
|
Enterprise Value (EV)
1 |
172,623
|
164,967
|
249,351
|
191,736
|
184,700
|
180,807
|
180,360
|
171,184
|
P/E ratio
|
24.5
x
|
-251
x
|
12.1
x
|
5.59
x
|
9.68
x
|
-18.4
x
|
51.6
x
|
24.3
x
|
Yield
|
4.73%
|
5.71%
|
3.88%
|
4.3%
|
4.69%
|
5.12%
|
4.87%
|
4.91%
|
Capitalization / Revenue
|
0.86
x
|
0.69
x
|
0.95
x
|
0.61
x
|
0.58
x
|
0.59
x
|
0.59
x
|
0.56
x
|
EV / Revenue
|
0.95
x
|
0.87
x
|
1.12
x
|
0.7
x
|
0.71
x
|
0.76
x
|
0.74
x
|
0.67
x
|
EV / EBITDA
|
7.09
x
|
7.76
x
|
6.58
x
|
2.94
x
|
4.29
x
|
11
x
|
7.3
x
|
5.74
x
|
EV / FCF
|
-113
x
|
-45.8
x
|
34.1
x
|
7.87
x
|
62.6
x
|
-70.2
x
|
12.8
x
|
13.9
x
|
FCF Yield
|
-0.88%
|
-2.18%
|
2.93%
|
12.7%
|
1.6%
|
-1.43%
|
7.79%
|
7.2%
|
Price to Book
|
1.39
x
|
1.26
x
|
1.84
x
|
1.18
x
|
1.01
x
|
0.97
x
|
1.06
x
|
1.06
x
|
Nbr of stocks (in thousands)
|
56,958
|
56,980
|
57,027
|
56,877
|
56,910
|
56,819
|
-
|
-
|
Reference price
2 |
2,746
|
2,278
|
3,715
|
2,905
|
2,666
|
2,514
|
2,514
|
2,514
|
Announcement Date
|
5/14/19
|
5/13/20
|
5/14/21
|
5/12/22
|
5/12/23
|
5/10/24
|
-
|
-
|
Fiscal Period: Maart |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
181,415
|
188,712
|
223,016
|
272,944
|
260,908
|
236,950
|
242,200
|
254,680
|
EBITDA
1 |
24,352
|
21,269
|
37,886
|
65,116
|
43,075
|
16,483
|
24,716
|
29,847
|
EBIT
1 |
14,648
|
9,939
|
25,392
|
50,490
|
23,381
|
-4,043
|
4,462
|
9,726
|
Operating Margin
|
8.07%
|
5.27%
|
11.39%
|
18.5%
|
8.96%
|
-1.71%
|
1.84%
|
3.82%
|
Earnings before Tax (EBT)
1 |
11,375
|
6,113
|
20,823
|
41,323
|
22,907
|
-7,619
|
2,633
|
7,400
|
Net income
1 |
6,386
|
-516
|
17,468
|
29,599
|
15,676
|
-7,553
|
2,769
|
5,874
|
Net margin
|
3.52%
|
-0.27%
|
7.83%
|
10.84%
|
6.01%
|
-3.19%
|
1.14%
|
2.31%
|
EPS
2 |
111.9
|
-9.060
|
306.4
|
519.6
|
275.5
|
-132.8
|
48.72
|
103.3
|
Free Cash Flow
1 |
-1,524
|
-3,604
|
7,315
|
24,367
|
2,952
|
-2,577
|
14,046
|
12,321
|
FCF margin
|
-0.84%
|
-1.91%
|
3.28%
|
8.93%
|
1.13%
|
-1.09%
|
5.8%
|
4.84%
|
FCF Conversion (EBITDA)
|
-
|
-
|
19.31%
|
37.42%
|
6.85%
|
17.03%
|
56.83%
|
41.28%
|
FCF Conversion (Net income)
|
-
|
-
|
41.88%
|
82.32%
|
18.83%
|
-
|
507.2%
|
209.75%
|
Dividend per Share
2 |
130.0
|
130.0
|
144.0
|
125.0
|
125.0
|
125.0
|
122.5
|
123.5
|
Announcement Date
|
5/14/19
|
5/13/20
|
5/14/21
|
5/12/22
|
5/12/23
|
5/10/24
|
-
|
-
|
Fiscal Period: March |
2020 S1
|
2021 S1
|
2022 Q2
|
2022 S1
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 S1
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 S1
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
2025 S1
|
2025 Q3
|
2025 Q4
|
---|
Net sales
1 |
93,480
|
98,566
|
70,247
|
133,739
|
64,142
|
75,063
|
65,331
|
68,750
|
134,081
|
66,882
|
59,945
|
56,620
|
59,923
|
116,543
|
60,968
|
59,439
|
58,850
|
59,950
|
118,500
|
61,000
|
59,700
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
13,855
|
-
|
11,242
|
4,947
|
-
|
5,270
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
5,758
|
8,146
|
14,724
|
26,951
|
9,220
|
14,319
|
8,580
|
9,104
|
17,684
|
5,966
|
-269
|
-1,711
|
142
|
-1,569
|
422
|
-2,896
|
800
|
1,350
|
1,500
|
2,650
|
2,100
|
Operating Margin
|
6.16%
|
8.26%
|
20.96%
|
20.15%
|
14.37%
|
19.08%
|
13.13%
|
13.24%
|
13.19%
|
8.92%
|
-0.45%
|
-3.02%
|
0.24%
|
-1.35%
|
0.69%
|
-4.87%
|
1.36%
|
2.25%
|
1.27%
|
4.34%
|
3.52%
|
Earnings before Tax (EBT)
|
3,965
|
6,160
|
13,675
|
25,090
|
8,626
|
7,607
|
8,128
|
12,574
|
20,702
|
5,084
|
-2,879
|
-1,165
|
-425
|
-1,590
|
-1,646
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
2,544
|
5,102
|
11,176
|
19,519
|
5,999
|
4,081
|
5,587
|
9,966
|
15,553
|
3,236
|
-3,113
|
-1,120
|
-702
|
-1,822
|
-1,523
|
-4,208
|
280
|
870
|
700
|
1,433
|
1,637
|
Net margin
|
2.72%
|
5.18%
|
15.91%
|
14.59%
|
9.35%
|
5.44%
|
8.55%
|
14.5%
|
11.6%
|
4.84%
|
-5.19%
|
-1.98%
|
-1.17%
|
-1.56%
|
-2.5%
|
-7.08%
|
0.48%
|
1.45%
|
0.59%
|
2.35%
|
2.74%
|
EPS
|
44.67
|
89.52
|
-
|
342.2
|
105.4
|
-
|
98.25
|
-
|
273.4
|
56.84
|
-
|
-19.67
|
-12.33
|
-32.00
|
-26.78
|
-73.99
|
-22.51
|
2.462
|
-
|
19.70
|
38.52
|
Dividend per Share
2 |
65.00
|
50.00
|
-
|
62.00
|
-
|
-
|
-
|
-
|
62.00
|
-
|
-
|
-
|
62.00
|
62.00
|
-
|
63.00
|
-
|
62.50
|
-
|
-
|
62.50
|
Announcement Date
|
11/11/19
|
11/10/20
|
11/9/21
|
11/9/21
|
2/8/22
|
5/12/22
|
8/9/22
|
11/9/22
|
11/9/22
|
2/8/23
|
5/12/23
|
8/8/23
|
11/9/23
|
11/9/23
|
2/9/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: March |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
16,217
|
35,167
|
37,494
|
26,509
|
32,978
|
41,998
|
37,489
|
28,313
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
0.6659
x
|
1.653
x
|
0.9897
x
|
0.4071
x
|
0.7656
x
|
2.548
x
|
1.517
x
|
0.9486
x
|
Free Cash Flow
1 |
-1,524
|
-3,604
|
7,315
|
24,367
|
2,952
|
-2,577
|
14,046
|
12,321
|
ROE (net income / shareholders' equity)
|
5.7%
|
-0.5%
|
16%
|
23.2%
|
10.8%
|
-5.2%
|
2.58%
|
4.3%
|
ROA (Net income/ Total Assets)
|
6.11%
|
3.08%
|
10.8%
|
17.6%
|
7.53%
|
-2.46%
|
1.95%
|
2.63%
|
Assets
1 |
104,541
|
-16,779
|
161,984
|
168,317
|
208,151
|
307,071
|
142,015
|
223,064
|
Book Value Per Share
2 |
1,980
|
1,809
|
2,020
|
2,463
|
2,635
|
2,507
|
2,371
|
2,381
|
Cash Flow per Share
2 |
264.0
|
174.0
|
518.0
|
775.0
|
618.0
|
224.0
|
341.0
|
426.0
|
Capex
1 |
17,768
|
18,833
|
27,375
|
41,654
|
22,558
|
19,128
|
13,173
|
12,073
|
Capex / Sales
|
9.79%
|
9.98%
|
12.27%
|
15.26%
|
8.65%
|
8.07%
|
5.44%
|
4.74%
|
Announcement Date
|
5/14/19
|
5/13/20
|
5/14/21
|
5/12/22
|
5/12/23
|
5/10/24
|
-
|
-
|
Last Close Price
2,514
JPY Average target price
2,518
JPY Spread / Average Target +0.12% Consensus |
1st Jan change
|
Capi.
|
---|
| -6.81% | 923M | | -24.19% | 7.68B | | +67.56% | 4.31B | | +5.59% | 2.63B | | -2.45% | 2.66B | | -47.56% | 2.11B | | -17.86% | 1.7B | | -19.62% | 1.5B | | +12.59% | 1.16B | | -45.36% | 1.11B |
Medical & Diagnostic Laboratories
|